nach oben

Erschienen in:

08.02.2018 | Original Article

Association of interferon regulatory factor 5 (IRF5) gene polymorphisms with juvenile idiopathic arthritis

verfasst von: Samira Esmaeili Reykande, Arezou Rezaei, Maryam Sadr, Mahsima Shabani, Farnaz Najmi Varzaneh, Vahid Ziaee, Nima Rezaei

Erschienen in: Clinical Rheumatology | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Interferon regulatory factor 5 (IRF5) is a member of IRF family which induce signaling pathways and are involved in modulation of cell growth, differentiation, apoptosis, and immune system activity. Juvenile idiopathic arthritis (JIA) is an auto-inflammatory syndrome where the inflammatory markers are believed to play a fundamental role in its pathogenesis. In this study, we aimed to assess the association of IRF5 gene polymorphisms with susceptibility of JIA in Iranian population. Three IRF5 single-nucleotide polymorphisms (rs10954213 A/G, rs2004640 G/T, and rs3807306 G/T) were genotyped using TaqMan assays in 55 patients with JIA and 63 matched healthy individuals. The frequency of the IRF5 rs2004640 T allele was significantly higher (69 vs 45%, P value = 0.0013) in JIA group as compared to control. The frequency of the IRF5 rs 2004640 G allele was significantly higher in the control group in comparison to JIA group (54 vs 32%, P value = 0.001). Allele and genotype frequencies of the rs10954213 and rs3807306 did not show any significant difference between JIA and control group. IRF5 rs 2004640 T allele can be considered as a risk factor for the development of JIA and presence of rs 2004640 G may be act as protective factor.

Woo P (2006) Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2(1):28–34. https://doi.org/10.1038/ncprheum0084 CrossRefPubMed

Espinosa M, Gottlieb BS (2012) Juvenile idiopathic arthritis. Pediatr Rev 33(7):303–313. https://doi.org/10.1542/pir.33-7-303 CrossRefPubMed

Ravelli A, Martini A (2007) Juvenile idiopathic arthritis. Lancet 369(9563):767–778. https://doi.org/10.1016/S0140-6736(07)60363-8 CrossRefPubMed

Oberle EJ, Harris JG, Verbsky JW (2014) Polyarticular juvenile idiopathic arthritis—epidemiology and management approaches. Clin Epidemiol 6:379–393. https://doi.org/10.2147/CLEP.S53168 PubMedPubMedCentralCrossRef

Scardapane A, Breda L, Lucantoni M, Chiarelli F (2012) TNF-alpha polymorphisms in juvenile idiopathic arthritis: which potential clinical implications? Int J Rheumatol 2012:756291. https://doi.org/10.1155/2012/756291 CrossRefPubMedPubMedCentral

Zhao GN, Jiang DS, Li H (2015) Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease. Biochim Biophys Acta 1852(2):365–378. https://doi.org/10.1016/j.bbadis.2014.04.030 CrossRefPubMed

Hedl M, Abraham C (2012) IRF5 risk polymorphisms contribute to interindividual variance in pattern recognition receptor-mediated cytokine secretion in human monocyte-derived cells. J Immunol 188(11):5348–5356. https://doi.org/10.4049/jimmunol.1103319 CrossRefPubMedPubMedCentral

Dieguez-Gonzalez R, Calaza M, Perez-Pampin E, de la Serna AR, Fernandez-Gutierrez B, Castaneda S et al (2008) Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. Arthritis Rheum 58(5):1264–1274. https://doi.org/10.1002/art.23426 CrossRefPubMed

Miceli-Richard C, Comets E, Loiseau P, Puechal X, Hachulla E, Mariette X (2007) Association of an IRF5 gene functional polymorphism with Sjogren’s syndrome. Arthritis Rheum 56(12):3989–3994. https://doi.org/10.1002/art.23142 CrossRefPubMedPubMedCentral

10.

Ito I, Kawaguchi Y, Kawasaki A, Hasegawa M, Ohashi J, Hikami K, Kawamoto M, Fujimoto M, Takehara K, Sato S, Hara M, Tsuchiya N (2009) Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum 60(6):1845–1850. https://doi.org/10.1002/art.24600 CrossRefPubMed

11.

Jia X, Hu M, Lin Q, Ren H (2013) Association of the IRF5 rs2004640 polymorphism with rheumatoid arthritis: a meta-analysis. Rheumatol Int 33(11):2757–2761. https://doi.org/10.1007/s00296-013-2806-0 CrossRefPubMed

12.

Yanagimachi M, Naruto T, Miyamae T, Hara T, Kikuchi M, Hara R et al (2011) Association of IRF5 polymorphisms with susceptibility to macrophage activation syndrome in patients with juvenile idiopathic arthritis. J Rheumatol 38(4):769–774. https://doi.org/10.3899/jrheum.100655 CrossRefPubMed

13.

Juge PA, Gazal S, Constantin A, Mariette X, Combe B, Tebib J, Dougados M, Sibilia J, le Loet X, Dieudé P (2017) Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. RMD Open 3(2):e000448. https://doi.org/10.1136/rmdopen-2017-000448 CrossRefPubMedPubMedCentral

14.

Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW et al (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38(5):550–555. https://doi.org/10.1038/ng1782 CrossRefPubMed

15.

Cunninghame Graham DS, Manku H, Wagner S, Reid J, Timms K, Gutin A et al (2007) Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation. Hum Mol Genet 16(6):579–591. https://doi.org/10.1093/hmg/ddl469 CrossRefPubMed

16.

Kristjansdottir G, Sandling JK, Bonetti A, Roos IM, Milani L, Wang C, Gustafsdottir SM, Sigurdsson S, Lundmark A, Tienari PJ, Koivisto K, Elovaara I, Pirttila T, Reunanen M, Peltonen L, Saarela J, Hillert J, Olsson T, Landegren U, Alcina A, Fernandez O, Leyva L, Guerrero M, Lucas M, Izquierdo G, Matesanz F, Syvanen AC (2008) Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet 45(6):362–369. https://doi.org/10.1136/jmg.2007.055012 CrossRefPubMedPubMedCentral

17.

Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P, International League of Associations for Rheumatology (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–392PubMed

18.

Ehsan S, Amirzargar A, Yekaninejad MS, Mahmoudi M, Mehravar S, Moradi B, Nafissi S (2015) Association of HLA class II (DRB1, DQA1, DQB1) alleles and haplotypes with myasthenia gravis and its subgroups in the Iranian population. J Neurol Sci 359(1):335–342. https://doi.org/10.1016/j.jns.2015.11.021 CrossRefPubMed

19.

Ramos PS, Criswell LA, Moser KL, Comeau ME, Williams AH, Pajewski NM, Chung SA, Graham RR, Zidovetzki R, Kelly JA, Kaufman KM, Jacob CO, Vyse TJ, Tsao BP, Kimberly RP, Gaffney PM, Alarcón-Riquelme ME, Harley JB, Langefeld CD, for The International Consortium on the Genetics of Systemic Erythematosus (SLEGEN) (2011) A comprehensive analysis of shared loci between systemic lupus erythematosus (SLE) and sixteen autoimmune diseases reveals limited genetic overlap. PLoS Genet 7(12):e1002406. https://doi.org/10.1371/journal.pgen.1002406 CrossRefPubMedPubMedCentral

20.

Saad MN, Mabrouk MS, Eldeib AM, Shaker OG (2016) Identification of rheumatoid arthritis biomarkers based on single nucleotide polymorphisms and haplotype blocks: a systematic review and meta-analysis. J Adv Res 7(1):1–16. https://doi.org/10.1016/j.jare.2015.01.008 CrossRefPubMed

21.

Zhu W, Yu J, Qiu S, Liu H, Wang Y, Xu X, Shao L, Zhu L, Jiao Y, Liu F, Zhu X (2017) MiR-let-7a regulates anti-citrullinated protein antibody-induced macrophage activation and correlates with the development of experimental rheumatoid arthritis. Int Immunopharmacol 51:40–46. https://doi.org/10.1016/j.intimp.2017.08.001 CrossRefPubMed

22.

Garnier S, Dieude P, Michou L, Barbet S, Tan A, Lasbleiz S, Bardin T, Prum B, Cornelis F, for ECRAF (2007) IRF5 rs2004640-T allele, the new genetic factor for systemic lupus erythematosus, is not associated with rheumatoid arthritis. Ann Rheum Dis 66(6):828–831. https://doi.org/10.1136/ard.2006.061390 CrossRefPubMed

23.

Wang J, Yi L, Guo X, Liu M, Li H, Zou H, Gu Y, Tu W, Guo G, Yang L, Lai S, He D, Zhou X (2014) Association of the IRF5 SNP rs2004640 with systemic sclerosis in Han Chinese. Int J Immunopathol Pharmacol 27(4):635–638. https://doi.org/10.1177/039463201402700420 CrossRefPubMed

24.

Vosslamber S, van der Voort LF, van den Elskamp IJ, Heijmans R, Aubin C, Uitdehaag BM et al (2011) Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonbeta therapy in multiple sclerosis. Genes Immun 12(6):466–472. https://doi.org/10.1038/gene.2011.18 CrossRefPubMed

25.

Tang L, Chen B, Ma B, Nie S (2014) Association between IRF5 polymorphisms and autoimmune diseases: a meta-analysis. Genet Mol Res: GMR 13(2):4473–4485. https://doi.org/10.4238/2014.June.16.6 CrossRefPubMed

26.

Feng D, Sangster-Guity N, Stone R, Korczeniewska J, Mancl ME, Fitzgerald-Bocarsly P, Barnes BJ (2010) Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression. J Immunol 185(10):6003–6012. https://doi.org/10.4049/jimmunol.1000482 CrossRefPubMedPubMedCentral

27.

Cavanagh LL, Boyce A, Smith L, Padmanabha J, Filgueira L, Pietschmann P, Thomas R (2005) Rheumatoid arthritis synovium contains plasmacytoid dendritic cells. Arthritis Res Ther 7(2):R230–R240. https://doi.org/10.1186/ar1467 CrossRefPubMedPubMedCentral

28.

Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM, Fitzgerald KA, Golenbock DT (2005) The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem 280(17):17005–17012. https://doi.org/10.1074/jbc.M412584200 CrossRefPubMed

29.

Nordang GB, Viken MK, Amundsen SS, Sanchez ES, Flato B, Forre OT et al (2012) Interferon regulatory factor 5 gene polymorphism confers risk to several rheumatic diseases and correlates with expression of alternative thymic transcripts. Rheumatology 51(4):619–626. https://doi.org/10.1093/rheumatology/ker364 CrossRefPubMed

30.

Rueda B, Reddy MV, Gonzalez-Gay MA, Balsa A, Pascual-Salcedo D, Petersson IF et al (2006) Analysis of IRF5 gene functional polymorphisms in rheumatoid arthritis. Arthritis Rheum 54(12):3815–3819. https://doi.org/10.1002/art.22271 CrossRefPubMed

31.

Devauchelle V, Marion S, Cagnard N, Mistou S, Falgarone G, Breban M, Letourneur F, Pitaval A, Alibert O, Lucchesi C, Anract P, Hamadouche M, Ayral X, Dougados M, Gidrol X, Fournier C, Chiocchia G (2004) DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets. Genes Immun 5(8):597–608. https://doi.org/10.1038/sj.gene.6364132 CrossRefPubMed

Titel: Association of interferon regulatory factor 5 (IRF5) gene polymorphisms with juvenile idiopathic arthritis
verfasst von: Samira Esmaeili Reykande
Arezou Rezaei
Maryam Sadr
Mahsima Shabani
Farnaz Najmi Varzaneh
Vahid Ziaee
Nima Rezaei
Publikationsdatum: 08.02.2018
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 10/2018
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-018-4010-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2018

Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic

Analysis of predictive factors for treatment resistance and disease relapse in Takayasu’s arteritis

The benchmark dose estimation of reference levels of serum urate for gout

Microstructure of osteophytes in medial knee osteoarthritis

Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA